This article reports findings from a paper published in the Journal of Clinical Oncology that demonstrate a recent rise in double mastectomies among women diagnosed with cancer in one breast. It generally does a good job of explaining that the benefits of the treatment are unknown. It explores the question of what may motivate women to make this decision.
The anecdote is well chosen because the woman is a nurse and therefore more credible as someone making an informed choice. It also allows us to hear one woman explain how she made what she knows to be a decision based more on emotion than fact.
The article would have been stronger had it taken a closer look at the risks and benefits of the whole range of breast cancer treatments, and what risks a woman diagnosed with breast cancer faces of the cancer spreading, returning or killing her.
While cost is very unlikely to drive a decision about breast cancer treatment, it’s increasingly important for the media to educate readers about the true underlying costs of medical treatments. In this case, the reporter cites "higher costs" as one disadvantage of double mastectomy. This obligates the reporter to specify those costs.
To know how the cost of either a single or double mastectomy compares to the costs of lumpectomy plus radiation would have added additional value.
Generally the article does a good job of using data to show how the number of double mastectomies has increased over six recent years.
But there is one serious flaw: The report states that, "Women removing a single cancerous breast have a 1 percent chance per year of suffering cancer in the other breast." That sounds fearsome, and like a reasonable motivation to undergo double mastectomy. But we have no idea how that 1 percent compares to a woman of a similar age who has not been diagnosed, to a woman with high risk who has not been diagnosed, etc.
In addition, the reporter is rounding up from a recurrence rate of between .5 percent to .75 percent, as stated in the research article. The average reader may estimate a 40 year old woman with 40 more years life expectancy has risk of recurrence in other breast of 40 percent; but data suggest it is closer to 20 to 30 percent.
The article is also unclear about the evidence regarding mortality: Have no studies looked into the question of whether a double mastectomy increases lifespan, or are there studies that show no difference?
The report mentions slightly higher risks of surgical complications and infections. It would have been useful to specify how serious and frequent these outcomes are, but this is not a serious flaw.
The article fairly reports that the study was based on an analysis of several years of data gathered for a large government study and reported in a credible medical journal.
The report makes clear early on the limitation that this study could not explain reasons for women making the choice.
The reporter does nothing to exaggerate the risks of cancer spreading from one breast to the other. In fact, the reporter does a good job making clear that the risk is lower than many patients think.
The reporter interviews the lead author of the study, two additional credible medical experts and one patient. The patient, a nurse, is a more credible source than one often finds in news stories.
The article sufficiently compares bilateral and single mastectomy, and reports that the lumpectomy with radiation option is more common.
The article implies, accurately, that double mastectomy is available at any facility that provides breast cancer treatment.
The article makes clear that this is the first large federal study of the issue. As for the procedure itself, no claims are made for its novelty.
There is no evidence that the report relies on the journal’s press release.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like